[ad_1]
A medical worker displays the inactivated COVID-19 candidate vaccine developed by SinoPharm at the company’s candidate vaccine production facility on April 10. Photo: Xinhua
Vaccines developed by Chinese pharmaceutical company Sinopharm Group have now been used in nearly a million people, with no serious adverse reactions reported, with only a few people reporting mild symptoms, Sinopharm Chairman Liu Jingzhen said Wednesday, to the Chinese media.
The inoculation range of the vaccines has obviously been expanded, as some 100,000 people were injected with the vaccines developed by Sinopharm during the China International Import Expo last week, Liu said. Some 56,000 people had left the country after being vaccinated and none had been infected with the new coronavirus after the vaccination.
Sinopharm’s phase III clinical trials of two inactivated vaccines against the novel coronavirus have been conducted in dozens of countries and regions, including the United Arab Emirates, Egypt, Bahrain, Peru and Argentina, with more than 60,000 participants, Liu noted.
The director of the Chinese pharmaceutical company said that the vaccines developed by Sinopharm are leading the world in all aspects; in terms of vaccine research and development, clinical trials, as well as emergency production and use.
At the beginning of October 20, Liu revealed that China National Biotec Group Company is ready for mass production of vaccines and that its supply will be sufficient and safe. More than 10 countries had said they had tried using the vaccines.
Global times
